Reduced antibody response to streptavidin through site-directed mutagenesis

Protein Science

Volumn 10, Issue 3, 2001, Pages 491-503

  Meyer, Damon L ^a   Schultz, Jody ^a   Lin, Yukang ^a   Henry, Andrew ^c   Sanderson, James ^a   Jackson, Jeffrey M ^a   Goshorn, Steve ^a   Rees, Anthony R ^b   Graves, Scott S ^a,d  

^a Poniard Pharmaceuticals Inc   (United States)

^b UNIVERSITY OF BATH   (United Kingdom)

^c OXFORD LASERS LTD   (United Kingdom)

^d NONE   (United States)

Author keywords

Antigenicity; Site directed mutagenesis; Streptavidin; Variants

Indexed keywords

BACTERIAL PROTEIN; BIOTIN; CANCER ANTIBODY; EPITOPE; RADIOISOTOPE; RECEPTOR; STREPTAVIDIN; TETRAMER;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIGENICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; CRYSTALLOGRAPHY; DRUG SYNTHESIS; HYDROPHOBICITY; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOREACTIVITY; MOLECULAR INTERACTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN FOLDING; RABBIT; SITE DIRECTED MUTAGENESIS;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODY FORMATION; ANTIGENS; CARRIER PROTEINS; EPITOPES; HUMANS; MUTAGENESIS, SITE-DIRECTED; PROTEIN FOLDING; RABBITS; STREPTAVIDIN;

ANIMALIA; BACTERIA (MICROORGANISMS); ORYCTOLAGUS CUNICULUS;

EID: 0035100425     PISSN: 09618368     EISSN: None     Source Type: Journal    
DOI: 10.1110/ps.19901     Document Type: Article

References (51)

1. Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity
2. 90Y-DOTA-biotin
3. Engineered chimeric streptavidin tetramers as novel tools for bioseparations and drug delivery
4. Thermodynamic and structural consequences of flexible loop deletion by circular permutation in the streptavidin-biotin system
5. Recombinant staphylokinase variants with altered immunoreactivity. IV: Identification of variants with reduced antibody induction but intact potency
6. Hydrogen bonding, hydrophobic interactions and the failure of the rigid receptor hypothesis
7. The uses and properties of PEG-linked proteins
8. Reduction of immunogenicity by covalent modification of murine and rabbit immunoglobulins with oxidized dextrans of low molecular weight
9. Structural studies of the streptavidin binding loop
10. Monoclonal antibodies as reversible equilibrium carders of radiopharmaceuticals
11. Molecular modeling and preclinical evaluation of the humanized NR-LU-13 antibody
12. Crystal structure of core streptavidin determined from multiwavelength anomalous diffraction of synchrotron radiation
13. Incorporation of nonnatural amino acids into streptavidin through in vitro frame-shift suppression
14. VMD - Visual molecular dynamics
15. Protein engineering of antibody binding sites: Recovery of an anti-digoxin single-chain Fv analogue produced in Escherichia coli
16. Replacing the complementarity-determining regions in a human antibody with those from a mouse
17. Dictionary of protein secondary structure: Pattern recognition of hydrogen-bonded and geometrical features
18. Binding of biotin to streptavidin stabilizes intersubunit salt bridges between Asp61 and His87 at low pH
19. Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer
20. The quaternary structure of streptavidin in urea
21. Recombinant staphylokinase variants with reduced antigenicity due to elimination of B-lymphocyte epitopes
22. Elimination of a major inhibitor epitope in factor VIII
23. Polyethylene glycol modification of a galactosylated streptavidin clearing agent: Effects in immunogenicity and clearance of a biotinylated anti-tumor antibody
24. The potential of carboxypeptidase G2: Antibody conjugates as anti-tumor agents. II. In vivo localising and clearance properties in a choriocarcinoma model
25. Raster3D: Photorealistic molecular graphics
26. Site-specific prodrug activation by antibody-β-lactamase conjugates: Regression and long term growth inhibition of human colon carcinoma xenograft models
27. Dextran modification of Fab'-β-lactamase conjugate modulated by variable pretreatment of Fab' with amine-blocking reagents
28. Protein antigenicity: A thermodynamic approach
29. On the attribution of binding energy in antigen/antibody complexes McPc603, D1.3, and HyHEL-5
30. A possible procedure for reducing the immunogenicity of antibody variable domains while preserving their ligand-binding properties
31. Characterization and crystallization of core streptavidin
32. Comparison of surface accessible residues in human and murine immunoglobulin Fv domains. Implication for humanization of murine antibodies
33. A humanized antibody that binds to the Interleukin-2 receptor
34. Cooperative biotin binding by streptavidin, electrophoretic behavior and subunit association of streptavidin in the presence of 6M urea
35. Expression of a cloned streptavidin gene in Escherichia coli
36. Intersubunit contacts made by tryptophan 120 with biotin are essential for both strong biotin binding and biotin-induced tighter subunit association of streptavidin
37. Recombinant core streptavidins. A minimum-sized core streptavidin has enhanced structural stability and higher accessibility to biotinylated macro-molecules
38. Engineering subunit association of multisubunit proteins: A dimeric streptavidin
39. A tetravalent single chain antibody-streptavidin fusion protein for pretargeted lymphoma therapy
40. Activation of prodrugs by antibody-enzyme conjugates: A new approach to cancer therapy
41. Mapping the common antigenic determinants in avidin and streptavidin
42. Structural correlates of an anticarcinoma antibody: Identification of specificity-determining residues (SDRs) and development of a minimally immunogenic antibody variant by retention of SDRs only
43. Hypothesis for the control of clotting Factor VIII inhibitory antibodies by decreasing potency of helper T-cell-recognized epitopes in Factor VIII
44. Humanized antibodies as potential therapeutic drugs
45. Reshaping human antibodies: Grafting an antilysozyme activity
46. Mutagenesis of a flexible loop in streptavidin leads to higher affinity for the Strep-tag II peptide and improved performance in recombinant protein purification
47. Systemic immunotoxin therapy of cancer: Advances and prospects
48. Structural origins of high-affinity biotin binding to streptavidin
49. Crystallographic and thermodynamic comparison of natural and synthetic ligands bound to streptavidin
50. Structure-based design of synthetic azobenzene ligands for streptavidin
51. Epitope-specific tolerance induction with an engineered immunoglobulin